The European Union has launched the Choose Europe for Science initiative and pledged €500 million in funding to attract US ...

A shift is evident in the healthcare and biotech industry that is steadily moving toward a digital future. A future where data management plays an important role in shaping research, regulatory ...

ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market.

Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals ...

Philip Morris is expanding its medical cannabis strategy via Aurora and Avicanna. What it means for the future of Big Tobacco ...

McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the ...

EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placeboFindings support progression to a Phase 2b trial Glasgow ...

Ongoing policy issues in the U.S., including the Inflation Reduction Act and recent proposals under President Donald Trump’s administration, have wide ranging implications for the global ...

MassBio’s new report outlines several concerns, including NIH cuts undermining the research engine, FDA reductions delaying ...

Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health.

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles. While many countries have seen a decline in investment in recent years ...